Aurinia Pharmaceuticals Inc. Revenue
Aurinia Pharmaceuticals Inc. (AUPH) reported Revenue of $83.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $83.22M, a 18.87% increase year-over-year.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $77.70M, a 24.40% increase year-over-year.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $77.11M, a 28.81% increase year-over-year.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $73.47M, a 8.41% increase year-over-year.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $283.06M, a 20.38% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $235.13M, a 33.97% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $175.51M, a 30.95% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $134.03M, a 193.89% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.22M 10-Q · filed 2026-08-06 | $160.93M 10-Q · filed 2026-08-06 | $238.04M derived: sum of 3 quarters · filed 2026-08-06 | $311.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $77.70M 10-Q · filed 2026-05-07 | $154.82M derived: sum of 2 quarters · filed 2026-05-07 | $228.29M derived: sum of 3 quarters · filed 2026-05-07 | $298.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $77.11M 10-K · filed 2026-02-26 | $150.58M derived: sum of 2 quarters · filed 2026-02-26 | $220.59M derived: sum of 3 quarters · filed 2026-08-06 | $283.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | $73.47M 10-K · filed 2026-02-26 | $143.48M derived: sum of 2 quarters · filed 2026-08-06 | $205.94M 10-Q · filed 2025-11-04 | $265.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $70.01M 10-Q · filed 2026-08-06 | $132.47M 10-Q · filed 2026-08-06 | $192.34M derived: sum of 3 quarters · filed 2026-08-06 | $260.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $62.47M 10-Q · filed 2026-05-07 | $122.33M derived: sum of 2 quarters · filed 2026-05-07 | $190.10M derived: sum of 3 quarters · filed 2026-05-07 | $247.29M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $59.87M 10-K · filed 2026-02-26 | $127.64M derived: sum of 2 quarters · filed 2026-02-26 | $184.83M derived: sum of 3 quarters · filed 2026-02-26 | $235.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $67.77M 10-K · filed 2026-02-26 | $124.96M derived: sum of 2 quarters · filed 2026-02-26 | $175.27M 10-Q · filed 2025-11-04 | $220.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $57.19M 10-K · filed 2026-02-26 | $107.50M 10-Q · filed 2025-07-31 | $152.59M derived: sum of 3 quarters · filed 2026-02-26 | $207.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $50.30M 10-K · filed 2026-02-26 | $95.40M derived: sum of 2 quarters · filed 2026-02-26 | $149.91M derived: sum of 3 quarters · filed 2026-02-26 | $191.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $45.09M 10-K · filed 2025-02-27 | $99.61M derived: sum of 2 quarters · filed 2025-02-27 | $141.10M derived: sum of 3 quarters · filed 2025-02-27 | $175.51M 10-K · filed 2026-02-26 |
| 2023-09-30 | $54.52M 10-K · filed 2025-02-27 | $96.01M derived: sum of 2 quarters · filed 2025-02-27 | $130.42M 10-Q · filed 2024-11-07 | $158.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $41.49M 10-K · filed 2025-02-27 | $75.90M 10-Q · filed 2024-08-01 | $104.34M derived: sum of 3 quarters · filed 2025-02-27 | $160.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $34.41M 10-K · filed 2025-02-27 | $62.84M derived: sum of 2 quarters · filed 2025-02-27 | $118.62M derived: sum of 3 quarters · filed 2025-02-27 | $146.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $28.43M 10-K · filed 2024-02-15 | $84.21M derived: sum of 2 quarters · filed 2024-02-15 | $112.41M derived: sum of 3 quarters · filed 2024-02-15 | $134.03M 10-K · filed 2025-02-27 |
| 2022-09-30 | $55.78M 10-K · filed 2024-02-15 | $83.97M derived: sum of 2 quarters · filed 2024-02-15 | $105.59M 10-Q · filed 2023-11-02 | $129.00M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $28.19M 10-K · filed 2024-02-15 | $49.82M 10-Q · filed 2023-08-03 | $73.22M derived: sum of 3 quarters · filed 2024-02-15 | $87.89M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $21.63M 10-K · filed 2024-02-15 | $45.03M derived: sum of 2 quarters · filed 2024-02-15 | $59.70M derived: sum of 3 quarters · filed 2024-02-15 | $66.32M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $23.40M 10-K · filed 2023-02-28 | $38.07M derived: sum of 2 quarters · filed 2023-02-28 | $44.69M derived: sum of 3 quarters · filed 2023-02-28 | $45.60M 10-K · filed 2024-02-15 |
| 2021-09-30 | $14.67M 10-K · filed 2023-02-28 | $21.29M derived: sum of 2 quarters · filed 2023-02-28 | $22.20M 10-Q · filed 2022-11-03 | $72.23M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $6.62M 10-K · filed 2023-02-28 | $7.53M 10-Q · filed 2022-08-04 | $57.56M derived: sum of 3 quarters · filed 2023-02-28 | $57.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $914.00K 10-K · filed 2023-02-28 | $50.94M derived: sum of 2 quarters · filed 2023-02-28 | $50.97M derived: sum of 3 quarters · filed 2023-02-28 | $51.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $50.03M 10-K · filed 2022-02-28 | $50.06M derived: sum of 2 quarters · filed 2022-02-28 | $50.09M derived: sum of 3 quarters · filed 2022-02-28 | $50.12M 10-K · filed 2023-02-28 |
| 2020-09-30 | $29.00K 10-K · filed 2022-02-28 | $58.00K derived: sum of 2 quarters · filed 2022-02-28 | $88.00K 10-Q · filed 2021-11-03 | $117.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $29.00K 10-K · filed 2022-02-28 | $59.00K 10-Q · filed 2021-08-05 | $88.00K derived: sum of 3 quarters · filed 2022-02-28 | $318.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $30.00K 10-K · filed 2022-02-28 | $59.00K derived: sum of 2 quarters · filed 2022-02-28 | $289.00K derived: sum of 3 quarters · filed 2022-02-28 | $318.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $29.00K 10-K · filed 2021-02-24 | $259.00K derived: sum of 2 quarters · filed 2021-02-24 | $288.00K derived: sum of 3 quarters · filed 2021-02-24 | $318.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $230.00K 10-K · filed 2021-02-24 | $259.00K derived: sum of 2 quarters · filed 2021-02-24 | $289.00K derived: sum of 3 quarters · filed 2021-02-24 | |
| 2019-06-30 | $29.00K 10-K · filed 2021-02-24 | $59.00K derived: sum of 2 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $30.00K 10-K · filed 2021-02-24 | |||
| 2018-12-31 | $463.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |